{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T23:10:23Z","timestamp":1738451423867,"version":"3.35.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ccl.2008.07.001","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T09:27:07Z","timestamp":1224149227000},"page":"507-526","source":"Crossref","is-referenced-by-count":5,"title":["Angiotensin Receptor Blockers: Novel Role in High-Risk Patients"],"prefix":"10.1016","volume":"26","author":[{"given":"Usman","family":"Javed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash C.","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ccl.2008.07.001_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1007792820944","article-title":"Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure","volume":"11","author":"Kannel","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ccl.2008.07.001_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ccl.2008.07.001_bib3","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/jama.290.14.1884","article-title":"Lifetime risk for diabetes mellitus in the United States","volume":"290","author":"Narayan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2008.07.001_bib4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000060923.07573.F2","volume":"107","author":"Steinberger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.07.001_bib6","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1001\/jama.291.23.2847","article-title":"Prevalence of overweight and obesity among US children, adolescents, and adults, 1999\u20132002","volume":"291","author":"Hedley","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2008.07.001_bib7","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 8A","key":"10.1016\/j.ccl.2008.07.001_bib8","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/j.amjmed.2003.08.012","article-title":"Obesity as a cardiovascular risk factor","volume":"115","author":"Sowers","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/diacare.25.4.718","article-title":"Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers","volume":"25","author":"McFarlane","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ccl.2008.07.001_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British hypertension society guidelines for hypertension management (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ccl.2008.07.001_bib11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"336","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ccl.2008.07.001_bib13","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2008.07.001_bib14","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.diabres.2005.03.005","article-title":"Learning from large cardiovascular clinical trials: classical cardiovascular risk factors","volume":"68","author":"Kempler","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ccl.2008.07.001_bib15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"year":"2005","series-title":"National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005","author":"Centers for Disease Control and prevention","key":"10.1016\/j.ccl.2008.07.001_bib16"},{"key":"10.1016\/j.ccl.2008.07.001_bib17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure","volume":"42","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2008.07.001_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.jhh.1001650","article-title":"More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHeFT, HOPE-TOO and SYST-EUR2)","volume":"17","author":"Lip","year":"2003","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib19","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0735-1097(01)01126-3","article-title":"Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats","volume":"37","author":"Khaper","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjhyper.2004.07.001","article-title":"Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition","volume":"18","author":"Leiter","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib21","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/01.ATV.0000187465.55507.85","article-title":"Inhibition of the renin-angiotensin system prevents free fatty acid\u2013induced acute endothelial dysfunction in humans","volume":"25","author":"Watanabe","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 7","key":"10.1016\/j.ccl.2008.07.001_bib22","first-page":"S3","article-title":"Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence","volume":"16","author":"Unger","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","article-title":"Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)","volume":"99","author":"Andraws","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1592\/phco.26.9.1297","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis","volume":"26","author":"McCall","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccl.2008.07.001_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/107424840601100101","article-title":"Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a\u00a0review of the current evidence","volume":"11","author":"Tsouli","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ccl.2008.07.001_bib26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2174\/1381612053507413","article-title":"The reno-protective effect of the dual blockade of the renin angiotensin system (RAS)","volume":"11","author":"Luno","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"Suppl 2","key":"10.1016\/j.ccl.2008.07.001_bib27","first-page":"47","article-title":"Physiologic and pharmacologic implications of AT1 versus AT2 recpetors","volume":"5","author":"Chung","year":"1996","journal-title":"Blood Press"},{"key":"10.1016\/j.ccl.2008.07.001_bib28","doi-asserted-by":"crossref","first-page":"306S","DOI":"10.1016\/S0895-7061(97)00388-9","article-title":"Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues","volume":"10","author":"Johnston","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)00446-6","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ccl.2008.07.001_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/jmcc.1998.0843","article-title":"Endothelial dysfunction in human disease","volume":"31","author":"Drexler","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2796.1999.00449.x","article-title":"Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options","volume":"245","author":"Britten","year":"1999","journal-title":"J Intern Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.HYP.25.3.343","article-title":"Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle","volume":"25","author":"Fishel","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2008.07.001_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the rennin-angiotensin system on plasma PAI-1","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2008.07.001_bib34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects","volume":"339","author":"Gainer","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.07.001_bib36","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1161\/01.CIR.94.11.2756","article-title":"Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease","volume":"94","author":"Diet","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.07.001_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/FJC.0b013e31802b31a7","article-title":"Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes","volume":"49","author":"Willemsen","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccl.2008.07.001_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2005.12.036","article-title":"Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes","volume":"79","author":"Fiordaliso","year":"2006","journal-title":"Life Sci"},{"issue":"Suppl 4","key":"10.1016\/j.ccl.2008.07.001_bib39","first-page":"S84","article-title":"Angiotensin II stimulates insulin-independent glucose uptake in hypertrophied rat hearts","volume":"15","author":"Nascimben","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib40","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1210\/en.2003-0285","article-title":"Minireview: adiposity, inflammation, and atherogenesis","volume":"144","author":"Lyon","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ccl.2008.07.001_bib41","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/S0002-9149(97)00457-8","article-title":"Multiple signaling pathways involved in the metabolic effects of insulin","volume":"80","author":"Moule","year":"1997","journal-title":"Am J\u00a0Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib44","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","article-title":"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. The HOPE and HOPE-TOO Trial Investigators","volume":"293","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2008.07.001_bib45","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib46","doi-asserted-by":"crossref","first-page":"19626","DOI":"10.1016\/S0021-9258(17)32215-9","article-title":"Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat","volume":"269","author":"Schorb","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ccl.2008.07.001_bib47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/380541a0","article-title":"Tyrosine kinases in activation of the MAP-kinase cascade by G protein-coupled receptors","volume":"380","author":"Wan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ccl.2008.07.001_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/bj3100741","article-title":"Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart","volume":"310","author":"Saad","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.ccl.2008.07.001_bib49","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/00003495-200262090-00002","article-title":"The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications","volume":"62","author":"Bernobich","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ccl.2008.07.001_bib50","first-page":"133","article-title":"Angiotensin II Type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress","volume":"3","author":"Higashi","year":"2005","journal-title":"Curr Med Chem"},{"issue":"23","key":"10.1016\/j.ccl.2008.07.001_bib51","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2008.07.001_bib52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"year":"2004","series-title":"Seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute","key":"10.1016\/j.ccl.2008.07.001_bib53"},{"issue":"16","key":"10.1016\/j.ccl.2008.07.001_bib54","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"The Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib55","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2008.07.001_bib56","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/HJH.0b013e3282f52c36","article-title":"Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change","volume":"2","author":"Ikejima","year":"2008","journal-title":"J Hypertens"},{"issue":"9335","key":"10.1016\/j.ccl.2008.07.001_bib58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib59","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"9215","key":"10.1016\/j.ccl.2008.07.001_bib60","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial \u2013 the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejheart.2004.09.005","article-title":"Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT","volume":"6","author":"Krum","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccl.2008.07.001_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.07.001_bib63","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib66","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib67","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Breener","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib68","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib69","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.07.001_bib71","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ccl.2008.07.001_bib72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/01.HYP.0000036448.44066.53","article-title":"Angiotensin blockade prevents type 2 diabetes by formation of fat cells","volume":"40","author":"Sharma","year":"2002","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.ccl.2008.07.001_bib73","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00004872-200410000-00021","article-title":"Blockade of the rennin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity","volume":"22","author":"Furuhashi","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib74","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/00004872-200410000-00006","article-title":"Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity","volume":"22","author":"Kingston","year":"2004","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ccl.2008.07.001_bib75","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","article-title":"Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J Hypertens"},{"issue":"11A","key":"10.1016\/j.ccl.2008.07.001_bib76","doi-asserted-by":"crossref","first-page":"27C","DOI":"10.1016\/j.amjcard.2004.02.003","article-title":"Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetic mellitus and insulin resistance","volume":"93","author":"Mazzone","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib77","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/clc.4960261104","article-title":"Angiotensin II blockade: a therapeutic strategy with wide applications","volume":"26","author":"Aranda","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ccl.2008.07.001_bib78","doi-asserted-by":"crossref","first-page":"10J","DOI":"10.1016\/S0002-9149(03)00611-8","article-title":"Role of endothelial dysfunction in insulin resistance","volume":"92","author":"Hsueh","year":"2003","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2008.07.001_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s001250050880","article-title":"Angiotensin II and the endocrine pancreas; effects on islet blood flow and insulin secretion in rats","volume":"41","author":"Carlsson","year":"1998","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ccl.2008.07.001_bib80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1463-1326.2003.00265.x","article-title":"Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance","volume":"5","author":"Henriksen","year":"2003","journal-title":"Diabetes Obes Metab"},{"issue":"1 Pt. 2","key":"10.1016\/j.ccl.2008.07.001_bib81","first-page":"R332","article-title":"ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide","volume":"277","author":"Henriksen","year":"1999","journal-title":"Am J\u00a0Physiol"},{"issue":"8","key":"10.1016\/j.ccl.2008.07.001_bib82","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a north of Sweden efficacy evaluation (ALPINE study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib83","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200018080-00020","article-title":"Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients","volume":"18","author":"Azizi","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib84","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ccl.2008.07.001_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.ccl.2008.07.001_bib86","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.07.001_bib87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccl.2008.07.001_bib88","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ccl.2008.07.001_bib89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.ccl.2008.07.001_bib90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","article-title":"Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"24","author":"Haller","year":"2006","journal-title":"J Hypertens"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:32:59Z","timestamp":1738449179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865108000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0733865108000726"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2008.07.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}